RecruitingNCT06656728

CancerenD24 Screening as an Aid to the Clinician for the Diagnosis of Cancer

Clinical Validation Of A Diagnostic Cancerend24 Screening As An Aid To The Clinician For The Diagnosis Of Cancer In Healthy Subjects Attending The ICPC


Sponsor

Tel-Aviv Sourasky Medical Center

Enrollment

2,000 participants

Start Date

Sep 3, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of the researchers is to test whether the CancerenD24 index, an algorithm based on the quantitative value of CD24, CD11b, clinical and laboratory characteristics, developed in the laboratory can help in the early detection of a malignant disease in a population of healthy subjects.


Eligibility

Min Age: 40 Years

Inclusion Criteria3

  • Completion of all medical exams and questionnaires including cancer diagnoses, demographic data and other epidemiologic information
  • Willing and able to sign an informed consent
  • Age ≥40 years

Exclusion Criteria7

  • Age < 40 years
  • Pregnancy or breastfeeding
  • Any type of fever
  • Any cancer active at study entry or up to 5 years prior to study entry
  • Polyposis syndromes
  • Inflammatory bowel disease
  • Unwilling or unable to provide informed consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood-based liquid biopsy

Venous blood sample will be taken from the patient as part of the routine blood tests taken as part of the work at the Medical Center


Locations(1)

Integrated Cancer Prevention Center at the Tel Aviv Sourasky Medical Center Ichilov

Tel Aviv, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06656728


Related Trials